Eventide Asset Management 增持了 Viking Therapeutics 的股份，而 Wedbush 将 Voyager Therapeutics 评为“跑赢大盘”。 Eventide Asset Management boosted its stake in Viking Therapeutics, while Wedbush rated Voyager Therapeutics as 'outperform.'

埃文蒂德资产管理公司增加了维京治疗公司的股份20万股, Eventide Asset Management increased its stake in Viking Therapeutics by 200,000 shares, totaling 452,969 shares. 与此同时，Wedbush 开始对 Voyager Therapeutics 进行报道，评级为“跑赢大盘”。 Meanwhile, Wedbush initiated coverage on Voyager Therapeutics with an 'outperform' rating. 几个对冲基金调整了两家公司的持有量,反映了对生物技术库存的持续兴趣。 Several hedge funds have adjusted their holdings in both companies, reflecting ongoing interest in biotech stocks. Viking Therapeutics 的股价开盘价为 54.51 美元，而 Voyager 的股价为 5.78 美元，根据 Wedbush 的目标价，潜在上涨空间为 90.31%。 Viking Therapeutics' shares opened at $54.51, while Voyager's shares trade at $5.78 with a potential upside of 90.31% according to Wedbush's target price.